Study of UGN-104 for low-grade upper tract urothelial cancer
Part of Cancer clinical trials.
This trial tests a new treatment called UGN-104 for people with low-grade upper tract urothelial cancer (a type of cancer in the tube that carries urine from the kidney to the bladder). The treatment is given directly into the kidney area to kill cancer cells without surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have low-grade, non-invasive upper tract urothelial cancer with at least one tumor that is 5 to 15 mm after biopsy.
- Your cancer is in the part of the kidney that collects urine (the pyelocalyceal system, above the ureteropelvic junction).
- You have not had BCG treatment for bladder cancer in the last 6 months.
- You have no history of high-grade or invasive urothelial cancer in the last 2–5 years, and no history of carcinoma in situ.
- You have adequate kidney, liver, and blood cell function as shown by recent lab tests.
- You are not pregnant, breastfeeding, or planning pregnancy, and you agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people diagnosed with a rare type of cancer in the upper urinary tract (UTUC). Researchers hope to learn more about this condition and find better ways to treat it.
This trial tests an experimental drug, GEN1106, for people with solid tumors that have not responded to standard treatments. It aims to see if the drug can help shrink or control the cancer.
This trial tests a combination of an oral targeted drug (DV) and an immunotherapy (Toripalimab) to preserve kidney function in people with high-risk upper tract urothelial cancer (UTUC) who cannot have their kidney and ureter removed. It is for patients with only one kidney, reduced kidney function, or cancer in both ureters.
This study tests an experimental medicine called UGN-501 given directly into the bladder. It is for people whose bladder cancer has come back despite previous treatments, such as BCG therapy. The goal is to find the best dose and see how safe and effective it is.
This trial tests a new targeted therapy pill, dabogratinib, for people with low-grade upper tract urothelial carcinoma (a type of cancer in the tubes that carry urine from kidneys to bladder). It may be an option if you have tumor tissue left after a biopsy and haven't had certain prior treatments.
This Phase 2 trial studies whether a combination treatment can control high-grade upper tract urothelial cancer without removing the kidney and ureter (radical nephroureterectomy). It may help people who must avoid surgery or choose not to have it because of medical risk.
Hear when a new Upper Urinary Tract Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.